World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
57
Citations
11229
World Ranking
3589
National Ranking
316

Overview

Graeme Moyle is affiliated with the Chelsea and Westminster Hospital NHS Foundation Trust in the United Kingdom. The primary field of their research is Medicine, with a focus on HIV-related health complications and treatments.

The scientist's work covers several subfields, including Emergency Medicine, Infectious Diseases, Endocrinology, Diabetes and Metabolism, Virology, and Surgery. Their research topics emphasize HIV-related health complications and treatments, HIV/AIDS drug development and treatment, HIV Research and Treatment, Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, HIV/AIDS Research and Interventions, and Pharmacological Effects and Toxicity Studies.

Frequent coauthors collaborating with Moyle include:

  • Christoph Stephan
  • Mar Masiá
  • Éric Florence
  • Estebán Martínez
  • Christine Katlama

The scientist has published extensively in various venues, with repeated contributions to several journals. Their frequent publication venues are:

  • Journal of Antimicrobial Chemotherapy
  • Clinical Infectious Diseases
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
  • HIV Medicine
  • Open Forum Infectious Diseases

Recent papers authored or coauthored by Graeme Moyle include:

  • Evolocumab in HIV-Infected Patients With Dyslipidemia, 2020, Journal of the American College of Cardiology
  • Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV, 2020, PLoS ONE
  • Antiretrovirals and Weight Change: Weighing the Evidence, 2024, Clinical Infectious Diseases
  • Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study, 2021, European Journal of Pain
  • Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV, 2021, Journal of Antimicrobial Chemotherapy

Best Publications

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  • Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

    Mark E. Sharkey;Ian Teo;Thomas Greenough;Natalia Sharova

  • A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

    Graeme J. Moyle;Caroline A. Sabin;Jonathan Cartledge;Margaret Johnson

  • Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  • Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV-1 Infection

    Graeme J. Moyle;Adrian Wildfire;Sundhiya Mandalia;Howard Mayer

  • Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

    Frank A Post;Graeme J Moyle;Hans Jürgen Stellbrink;Pere Domingo

  • Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

    Graeme Moyle

  • Loss of Discrete Memory B Cell Subsets Is Associated with Impaired Immunization Responses in HIV-1 Infection and May Be a Risk Factor for Invasive Pneumococcal Disease

    Melanie Hart;Alan Steel;Sally A. Clark;Graeme Moyle

  • Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

    Graeme J Moyle;Debasis Datta;Sundhiya Mandalia;John Morlese

  • Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

    Elchonon M. Berkowitz;Graeme Moyle;Hans-Jürgen Stellbrink;Dirk Schürmann

  • Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.

    Mario Cruciani;Veronica Zanichelli;Giovanni Serpelloni;Oliviero Bosco

  • Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.

    Rachael Jones;Justin Stebbing;Mark Nelson;Graeme Moyle

  • Current knowledge and future prospects for the use of HIV protease inhibitors.

    Graeme Moyle;Brian G. Gazzard

  • The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen

    Laura Waters;Sundhiya Mandalia;Paul Randell;Adrian Wildfire

  • Antiretroviral nucleoside and nucleotide analogues and mitochondria.

    Andrea Cossarizza;Graeme Moyle

  • A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

    G J Moyle;C Baldwin;B Langroudi;S Mandalia

  • Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy.

    Graeme J. Moyle;Michelle Lloyd;Brian Reynolds;Christine Baldwin

  • Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

    Joel E. Gallant;Ellen Koenig;Jaime Andrade-Villanueva;Ploenchan Chetchotisakd

  • Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

    Graeme J Moyle;Edwin DeJesus;Pedro Cahn;Steve A Castillo

  • Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

    Richard B. Pollard;Jürgen K. Rockstroh;Giuseppe Pantaleo;David M. Asmuth

  • Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?

    Graeme Moyle

  • Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data

    Julian Falutz;Jean-Claude Mamputu;Diane Potvin;Graeme Moyle

  • Peripheral Neuropathy with Nucleoside Antiretrovirals

    Unknown

  • Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies.

    Graeme Moyle;Will Sawyer;Matthew Law;Janaki Amin

  • Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1

    Graeme Moyle;Edwin DeJesus;Marta Boffito;Rebecca S. Wong

  • Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.

    Bonaventura Clotet;François Raffi;David Cooper;Jean François Delfraissy

Frequent Co-Authors

Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Marta Boffito
Marta Boffito Imperial College London
Mark Nelson
Mark Nelson University of Vermont
David Back
David Back University of Liverpool
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine
Saye Khoo
Saye Khoo University of Liverpool
Paul E. Sax
Paul E. Sax Brigham and Women's Hospital
Edwin DeJesus
Edwin DeJesus Hanover University of Applied Sciences and Arts
Martin Fisher
Martin Fisher University of Sussex
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their microbiology studies, pursuing related online degrees offers flexibility and diverse career opportunities. Many programs, including some accredited online MPH programs easy to get into, provide accessible pathways to public health careers that complement microbiology knowledge.

Career options extend beyond traditional microbiology roles. For example, becoming a child specialist salary can be an attractive route for those focused on pediatric health and development, often aligning with biology and health science backgrounds.

Additionally, for individuals with non-traditional backgrounds or unique challenges, exploring the best degree for felons can open doors in healthcare fields, helping break barriers and build rewarding careers.

Another rapidly growing career pathway is becoming a functional medicine nurse, which blends holistic health practices with scientific knowledge — a path well-suited for those with a background in microbiology or health sciences.

Best Scientists Citing Graeme Moyle

Trending Scientists

Recently Published Articles